Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2 Lymphoid 2 Plasma cell 1 Myeloid 1 Dermatologic 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 374 Lenalidomide 206 Bortezomib 201 Cyclophosphamide 178 Melphalan 135 Calcium Dobesilate 120 daratumumab 107 pomalidomide 74 carfilzomib 74 fludarabine phosphate 71 Peripheral Blood Stem Cell Transplantation 66 Thalidomide 57 Filgrastim 57 Mycophenolic Acid 56 Busulfan 55 Tacrolimus 48 Granulocyte Colony-Stimulating Factor 47 ixazomib 45 fludarabine 45 Whole-Body Irradiation 44 dexamethasone acetate 36 Cyclosporine 35 isatuximab 34 Etoposide 34 Antilymphocyte Serum 32 dexamethasone 21-phosphate 30 elotuzumab 28 auricularum 27 Prednisone 27 plerixafor 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × letermovir × Plasma cell × Clear all

NCT06920251 2025-12-03

OPTIMUS-EL

Seoul National University Hospital

Phase 2 Recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡